论文部分内容阅读
目的观察葡甘聚糖(魔芋的主要成份)对2型糖尿病患者的血糖、血脂以及血压等的影响,同时观察葡甘聚糖用于2型糖尿病患者的耐受性。方法随机选择124例2型糖尿病患者在不改变原有治疗的情况下给予葡甘聚糖,并与随机同期选择124例2型糖尿病患者对照,12周后评价葡甘聚糖改善血糖、血脂以及血压等效果。结果治疗12周后,服用葡甘聚糖的糖尿病患者空腹血糖(FPG)水平下降(1.26±1.71)mmol/L(P<0.001)、餐后2小时血糖(2hPG)水平下降(2.15±2.18)mmol/L(P<0.001)、HbAlc水平下降(0.97±1.14)%(P<0.001)、总胆固醇(TC)水平下降(0.31±0.76)mmol/(P<0.001)、低密度脂蛋白(LDL-C)水平下降(0.32±0.85)mmol/l(P<0.01)。患者经过12周服用葡甘聚糖治疗,有1.6%的患者发生轻度胃肠道不良反应,未发生相关的严重不良事件。结论葡甘聚糖有显著改善2型糖尿病人高血糖的作用,能减少和延缓葡萄糖的吸收,并有助于改善糖尿病患者血脂代谢异常,有较好的安全性和耐受性。
Objective To observe the effect of glucomannan, the main component of konjac, on the blood sugar, blood lipid and blood pressure in patients with type 2 diabetes mellitus, and to observe the tolerance of glucomannan to type 2 diabetes mellitus. Methods A total of 124 patients with type 2 diabetes were randomly assigned to receive glucomannan without changing the original treatment and compared with 124 patients with type 2 diabetes mellitus randomly. After 12 weeks, glucomannan was administered to improve blood glucose, blood lipid, Blood pressure and other effects. Results After 12 weeks of treatment, the level of fasting plasma glucose (FPG) decreased (1.26 ± 1.71) mmol / L (P <0.001) in diabetic patients taking glucomannan and decreased (2.15 ± 2.18) 2 hours postprandial (P <0.001), HbAlc levels (0.97 ± 1.14)% (P <0.001) and total cholesterol (TC) levels decreased by 0.31 ± 0.76 mmol / -C) decreased (0.32 ± 0.85) mmol / l (P <0.01). Patients treated with glucomannan after 12 weeks, mild gastrointestinal adverse reactions occurred in 1.6% of patients, no serious adverse events related to it. Conclusion Glucomannan can significantly improve the effect of hyperglycemia in type 2 diabetes mellitus, reduce and delay the absorption of glucose, and help to improve the blood lipid metabolism in diabetic patients with better safety and tolerability.